The simultaneous inhibition of the CXCR4—SDF-1 and PD-1—PD-L1 pathways and the depletion of effector Tregs may enhance the antitumor immune response and reduce mortality in ovarian cancer patients [242,308]. Here, CXCR4 is linked to ovarian carcinoma.